Amyloid β (Reverse Human, 16-10) 

Catalog Number: B2024168 (1 mg)

Amyloid β (Aβ) is a peptide derived from the amyloid precursor protein (APP). This product has been used as a molecular tool for various biochemical applications. It has also been used in a wide array of other chemical and immunological applications. Custom bulk amounts of this product are available upon request.

Lot number: Batch Dependent

Expiration Date: Batch dependent

Amount: 1 mg

Molecular Weight or Concentration: 940.01 g/mol

Supplied as: Lyophilized Powder

Applications: a molecular tool for various biochemical applications

Storage: −20°C

Keywords: Amyloid beta, Aβ, Amyloid beta peptide, Amyloid beta protein, Beta-amyloid, A4 protein, Alzheimer’s beta peptide, Amyloid precursor protein fragment

Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:

1. Selkoe, D. J. (2001). Alzheimer’s disease: genes, proteins, and therapy. *Physiological Reviews*, 81(2), 741-766.

2. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. *Science*, 297(5580), 353-356.

3. Haass, C., & Selkoe, D. J. (2007). Soluble and insoluble beta-amyloid: a key role for protofibrils in Alzheimer’s disease. *The American Journal of Pathology*, 171(1), 1-5.

4. Karran, E., & Walker, L. (2013). The amyloid cascade hypothesis: are we poised for success? *Nature Reviews Drug Discovery*, 12(10), 751-752.

5. Selkoe, D. J. (2012). Alzheimer’s disease: a central role for amyloid. *Nature Reviews Neuroscience*, 13(8), 494-504.

6. Zlokovic, B. V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. *Nature Reviews Neuroscience*, 12(12), 933-948.

7. De Strooper, B., & Karran, E. (2016). The cellular phase of Alzheimer’s disease. *Cell*, 164(4), 603-615.

8. Cummings, J. (2016). The role of biomarkers in Alzheimer’s disease drug development. *Nature Reviews Drug Discovery*, 15(5), 327-328.

9. Vellas, B., et al. (2017). Designing drug trials for Alzheimer’s disease: a new approach. *Nature Reviews Drug Discovery*, 16(1), 1-2.

10. Bateman, R. J., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. *New England Journal of Medicine*, 367(9), 795-804.

https://pubmed.ncbi.nlm.nih.gov/?term=Amyloid β (Reverse Human)

견적 문의: aibiohub@aibiohub.co.kr  홈페이지: www.aibiohub.co.kr 

견적 문의: https://aibiohub.co.kr/estimate/write